This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ampio's Eye Drug Approval Strategy Dealt Another Credibility Hit

GREENWOOD VILLAGE, Colo. ( TheStreet) -- The announcement by Regeneron Pharmaceuticals (REGN - Get Report) on Tuesday that it will accelerate diabetic macular edema approval (DME) filings for its lead drug Eylea by one year is another reminder of the ridiculous and misleading statements made by Ampio Pharmaceuticals (AMPE - Get Report) regarding the clinical development of its DME drug candidate Optina.

Ampio tells investors that a single, "pivotal" phase III study of Optina lasting just 12 weeks will be sufficient to seek FDA approval as a treatment for DME.

That's a remarkable claim, completely untethered from reality.

Consider Regeneron, which announced positive, one-year results from two large phase III studies of Eylea in DME on Tuesday morning. Regeneron had thought that two years of positive data from these trials would be necessary before supplemental new drug applications in DME could be filed in the U.S. and Europe.

Not so any longer. Regeneron will file Eylea for DME approval before the end of this year based on the one-year trial results. Bayer, which markets Eylea in Europe for Regeneron, will do the same in Europe.

"Concerted discussions with the FDA led us to make that change," said Regeneron CEO Leonard Schleifer to Forbes' Matt Herper.

Regeneron spends considerable time and energy convincing FDA to review Eylea based on a year's worth of data, yet Ampio wants investors to believe the same regulators will be copacetic with a single clinical trial of 12 weeks on Optina.

Absurd.

A previous study of Optina in DME failed.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMPE $2.35 0.00%
REGN $515.37 0.00%
AAPL $132.04 0.00%
FB $80.55 0.00%
GOOG $539.79 0.00%

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs